Why the study?
What is the prevalence and profile of neutralizing antibodies to AAV2 and AAV8 in human subjects aged 0 to 18 years?
What is the prevalence and profile of neutralizing antibodies to AAV2 and AAV8 in human subjects aged 0 to 18 years?
Answers are grounded in this paper and cite their sources.
The prevalence of neutralizing antibodies to AAV vectors fluctuates significantly from birth through adolescence, which may impact the timing and efficacy of AAV-mediated gene therapies in pediatric populations.
Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.
No takes yet. Share an insight, caveat, or question.
Calcedo et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: